Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biomarkers Diagnose and Predict Acute Pancreatitis

By LabMedica International staff writers
Posted on 08 Jul 2021
Acute pancreatitis (AP) is an inflammatory reaction caused by the activated pancreatic enzymes in the pancreas, which leads to subsequent pancreatic autodigestion, edema, hemorrhage, necrosis, and even distal organ dysfunction.

Conventional biomarkers such as amylase, lipase, C-reactive protein (CRP), and leukocytes are less specific in assessing the severity of AP. More...
Control of the systemic inflammatory response is a key factor in the prognosis of AP; thus, pro-inflammatory markers can be mined as potential diagnostic and prognostic indicators of AP.

Clinical Laboratorians at the Zhejiang University School of Medicine (Hangzhou, China) included in a study 451 participants, including 343 AP patients and 108 healthy controls. According to the clinical outcome within 28 days, all patients were divided into the deceased group and survival group, while the survival group included four subgroups based on the clinical manifestations: pancreatic infection and necrosis, pancreatic tissue accumulation, extrapancreatic infection, and new-onset diabetes, some of which overlapped with each other.

Systemic inflammatory response syndrome (SIRS) score were evaluated for each patient within 24, 24, and 48 hours of admission, respectively. Laboratory indicators included were plasma levels of plasma procalcitonin (PCT), heparin-binding protein (HBP), and interleukin-6 (IL-6) on days 1, 3, 7, and 10 after admission for all patients in the study. Patient outcomes were recorded: death, infectious pancreatic necrosis, necrotic tissue accumulation, septic shock, new-onset diabetes, and extrapancreatic infection.

The investigators reported that a statistically significant increase in the mean plasma analyte levels was detected in the study group compared to the control group. Multivariate comparison showed that plasma levels of PCT, HBP, and IL-6 were all significantly different among the three groups at different sampling times (1st, 3rd, 7th, and 10th day of admission). The combination of the three indicators had significantly higher diagnostic value than either the individual markers or pairwise combinations. The levels of the three were all significantly higher in severe acute pancreatitis (SAP) patients than in non-SAP patients. The patients with high levels had a worse prognosis than those with low levels.

The authors concluded that the combined detection of plasma PCT, HBP, and IL-6 provided a new idea for the diagnosis of patients with AP; increased concentrations of PCT, HBP, or IL-6 within three days of admission were associated with AP severity and poor prognosis; high concentrations of PCT, HBP, or IL-6 may be the useful predictors of SAP and the independent risk factors for AP. The study was published on June 21, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Zhejiang University School of Medicine


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.